| Literature DB >> 28878139 |
Patrícia de Souza Bonfim-Mendonça1, Isis Regina Grenier Capoci2, Flávia Kelly Tobaldini-Valerio3, Melyssa Negri4, Terezinha Inez Estivalet Svidzinski5.
Abstract
Glucans are a group of glucose polymers that are found in bacteria, algae, fungi, and plants. While their properties are well known, their biochemical and solubility characteristics vary considerably, and glucans obtained from different sources can have different applications. Research has described the bioactivity of β-glucans extracted from the algae of the Laminaria genus, including in vivo and in vitro studies assessing pro- and anti-inflammatory cytokines, vaccine production, inhibition of cell proliferation, and anti- and pro-oxidant activity. Thus, the objective of this article was to review the potential application of β-glucans from Laminaria spp. in terms of their immunomodulatory properties, microorganism host interaction, anti-cancer activity and vaccine development.Entities:
Keywords: Laminaria; defense; glucans; immunomodulatory properties; β-glucan
Mesh:
Substances:
Year: 2017 PMID: 28878139 PMCID: PMC5618472 DOI: 10.3390/ijms18091629
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Schematic representation of the basic molecular structures of LAM: (A) β-(1-3)-d-glucose linked; and (B) β-(1-6)-d-glucose branch. N: number of specific repetitions of β-(1-3)-d-glucose linked; N *: number of specific repetitions of β-(1-6)-d-glucose branch, both according to the species Laminaria spp.
Immunomodulatory properties of β-glucans from genus Laminaria spp.
| Source | Product | Immunomodulation | Type of Study | Reference |
|---|---|---|---|---|
| Laminarin | Increase in the release of H2O2, calcium, NO, MCP-1, VEGF, leukemia inhibitory factor, and G-CSF Enhancement of expression of STAT1, STAT3, Jun, Fos, and COX-2 mRNA | In vitro (murine RAW 264.7 macrophages) | [ | |
| Kombu and ganiashi | Ganiashi SPS increased NO production | In vitro (Caco-2 cells and RAW 264.7 macrophages) | [ | |
| Laminarin | Increase in oxidant and nitrogen species production Reduction of pro-inflammatory cytokines IL8, IL1-β and TNF-α | In vitro (human neutrophils and total leukocytes) | [ | |
Inhibition of phagocytosis | In vitro (murine RAW 264.7 macrophages) | [ | ||
Weak ROS production Weak lymphocyte proliferation stimulus | In vitro (monocytes, neutrophils, and lymphocytes in pigs) | [ | ||
Weak production of cytokines IL-1β, IL-6, IL-8, and TNF-α | In vitro (whole blood cultures) | [ | ||
| - | Laminarin | Enhancement of expression of the genes cytokines ( | In vivo (fish, | [ |
| Laminarin | Increased phagocytic activity Enhancement of expression IL-1β and IFN-γ transcripts Increased serum IgM level | In vivo (fish, | [ | |
| Brown Algae | Laminarin | Decrease in number of serum monocytes, NO2, and TNF-α, after challengewith LPS Modulation of intra-hepatic immune cells | In vivo (Wistar rats) | [ |
| - | Laminarin polysaccharides | Increased GPx and SOD activity, after sepsis Reduction of MDA concentrations, after sepis | In vivo (Sprague-Dawley rats) | [ |
| Laminarin | Enhancement of IL-6 and IL-8 cytokine gene expression | In vivo (pig) | [ | |
| Laminarin | No stimulation of any pro- or anti-inflammatory cytokines in ileum. Down-regulation of anti-inflammatory cytokines gene expression ( Reduction of pro-inflammatory markers in the colon | In vivo (pig) | [ | |
Decreased | In vivo(pig) | [ | ||
Increase in | In vivo (pig) | [ | ||
| SWE (Laminarin + Fucoidan) | Increased IgG concentrations, in colostrum | In vivo (pig) | [ | |
Increase Increase | In vivo (pig) | [ | ||
Increase | In vivo (pig) | [ | ||
| Laminarin + Fucoidan | Lower expression of IL-6, IL-17a, and IL-1-β mRNA, in the colon, when using only LAM | In vivo (pigs) | [ | |
| Laminarin | Increased IFN-γ, in the ileum | In vivo (pigs) | [ | |
| Laminarin + Fucoidan | Down-regulated IL-6, IL-22, TNF- α and | In vivo (pigs) | [ |
Antitumor activity of β-glucans from seaweed of the genus Laminaria spp.
| Source | Extract | Applicability | Type of Study | Reference |
|---|---|---|---|---|
| Laminarin | Dose-dependent induction of cell death Increase in the percentage of cells in the sub-G1 and G2-M phases Inhibition of heregulin-stimulated phosphorylation of ErbB2 Decrease in cellular proliferation | In vitro (HT-29 colon cancer cells) | [ | |
| Sulfated polysaccharide fraction (LJSP) | Highest inhibitory effect on cervical carcinoma U14 cells among five tumor cell lines In vivo, LJSP inhibited tumor growth and enhanced spleen and thymus indices and bodyweight of U14 tumor-bearing mice Prominent antitumor activity and low toxic effects | In vitro (HeLa (cervical carcinoma), U14 (cervical carcinoma), A549 (lung carcinoma), Bel-7402 (hepatoma), and HCT-8 (colon carcinoma) cells) In vivo (female Kunming mice, 6–8 weeks old; weight, 18–22 g) | [ | |
| Novel polysaccharide WPS-2-1 | Dose-dependent antitumor activity against A375 and BGC823 cells Lower cytotoxic effects on vascular smooth muscle cells | In vitro (human gastric carcinoma cell line BGC823, human melanoma cell line A375, and aortic vascular smooth muscle cells) | [ | |
| Novel polysaccharide WPS-2-1 | Induction of apoptosis associated with alterations in the expression of Bcl-2 family proteins Mitochondrial apoptotic pathway involvement in WPS-2-1-induced apoptosis, which included the loss of the mitochondrial membrane and activation of caspase-3/9 Effective inhibition of proliferation of A375 cells in vitro and induction of apoptosis via mitochondrial apoptotic pathway | In vitro (human melanoma cell line A375) | [ | |
| Laminarin polysaccharides (LP1) | Suppression of apoptotic death around three- or two-fold Prolonged cell survival in culture at a rate of 20–30% | In vitro (mouse thymocytes) | [ |
Applicability of β-glucans from seaweed of the genus Laminaria spp. in vaccines against different pathogenic fungi.
| Source | Extract | Applicability | Type of study | Reference |
|---|---|---|---|---|
| Laminarin | Vaccine against | In vivo (female CD2F1 mice, 4 weeks old; Harlan) | [ | |
| Vaccine against | In vivo (female CD2F1 mice, 4 weeks old; Harlan-Nossan) | [ | ||
| Vaccine against | In vivo (female BALB/c and BALB/cnu/nude mice, 6–8 weeks old) | [ | ||
Increase in levels of TGF-β and IL-6 High titers of Ab that recognizes | In vitro (mouse RAW264.7 macrophages; bone marrow-derived DCs [BMDCs]) | [ |